Compare XYF & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XYF | IMUX |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | China | United States |
| Employees | N/A | 66 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.4M | 152.6M |
| IPO Year | 2018 | 2013 |
| Metric | XYF | IMUX |
|---|---|---|
| Price | $5.04 | $11.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | 133.7K | ★ 2.2M |
| Earning Date | 05-18-2026 | 05-14-2026 |
| Dividend Yield | ★ 11.34% | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.90 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.30 | $0.51 |
| 52 Week High | $20.36 | $11.29 |
| Indicator | XYF | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 59.05 | 85.94 |
| Support Level | $4.86 | $0.75 |
| Resistance Level | $5.07 | N/A |
| Average True Range (ATR) | 0.21 | 0.65 |
| MACD | 0.02 | 0.82 |
| Stochastic Oscillator | 91.93 | 97.85 |
X Financial is a Cayman Islands-based technology-driven personal finance company. Along with its subsidiaries, the firm provides diversified investment opportunities to investors in China through its wealth management platform, Xiaoying Wealth Management. Loan products offered by the company include Xiaoying Card Loan, Xiaoying Preferred Loan, and Xiaoying Housing Loan. The company generates revenue from loan facilitation service, post-origination service, and guarantee services provided.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.